Overview

• Siemens AG announced the $5.1 billion acquisition of U.S.-based Dotmatics, a leader in AI-driven R&D software for drug discovery, with the deal expected to close in the first half of 2026.
• The acquisition is part of Siemens' strategy to expand its Life Sciences portfolio and enhance its Xcelerator platform with AI-powered PLM software capabilities.
• Dotmatics is projected to generate over $300 million in revenue in 2025 with an adjusted EBITDA margin above 40%, contributing to Siemens' profitability and growth.
• Siemens anticipates significant revenue synergies, with medium-term contributions of $100 million annually, accelerating to over $500 million per year in the long term.
• The transaction will be financed primarily through share sales of Siemens' listed companies, including Siemens Healthineers, reflecting the company's commitment to its digital and AI-driven transformation.